Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
The Endotrophin Biomarker, NordicPRO-C6™, as a Marker for Intestinal Fibrosis in Crohn’s Disease
May 3, 2025
Introduction
Crohn’s disease (CD) is a chronic inflammatory condition that often progresses to fibrostenotic complications due to imbalanced extracellular matrix (ECM) remodeling. Fibrosis, a result of excessive ECM deposition, is challenging to manage as current treatments do not prevent or reverse these processes. Diagnostic tools are limited, as endoscopy only visualizes the mucosa and imaging struggles to distinguish fibrosis from inflammation. Type VI collagen is associated with fibrogenesis and is also expressed by adipocytes which may suggest that type VI collagen could also be associated with creeping fat in CD patients with fibrostenotic structures.
This study aimed to evaluate the endotrophin marker, nordicPRO-C6™, and its ability to distinguish stenosing from luminal CD, predict postoperative recurrence, and correlation with histological fibrosis severity.
Poster
Conclusion
NordicPRO-C6™ as an ECM marker demonstrated potential in characterizing fibrosis in CD and distinguishing stenosing from luminal phenotype. Evidence from tissue samples suggested that increased collagen VI gene expression was associated with the development of complicated disease featuring strictures. NordicPRO-C6™ levels decreased following resection but returned to baseline by 3 months, which may indicate a risk of recurrent fibrosis formation. These findings highlight nordicPRO-C6™ as a promising non-invasive tool for monitoring disease stage and fibrosis. Extended follow-up studies are crucial to validate the clinical utility of nordicPRO-C6™ and to further explore its role in guiding personalized treatment strategies.
